Review
Nature Reviews Drug Discovery 5, 903-918 (November 2006) | doi:10.1038/nrd2145
PI3K
inhibition: towards an 'aspirin of the 21st century'?
Thomas Rückle1, Matthias K. Schwarz1 & Christian Rommel1 About the authors
Abstract
Class IB phosphatidylinositol 3-kinase p110
(PI3K) has gained increasing attention as a promising drug target for the treatment of inflammatory disease. Extensive target-validation data are available, which are derived from studies using both pharmacological and genetic tools. More recent findings have uncovered further therapeutic applications for PI3K inhibitors, opening up potentially huge opportunities for these drugs. Several companies have been pursuing small-molecule PI3K inhibitor projects, but none of them has progressed to the clinic yet. Here, we discuss the insights gained so far and the main challenges that are emerging on the path to developing PI3K inhibitors for the treatment of human disease.
- View At a Glance
Author affiliations
- Serono Pharmaceutical Research Institute, Serono International S.A., 14 Chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland.
Correspondence to: Matthias K. Schwarz1 Email: matthias.schwarz@serono.com
Correspondence to: Christian Rommel1 Email: christian.rommel@serono.com
Published online 13 October 2006
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Hypothetical biotechnology mega-mergersNature Biotechnology Strategic Planning (01 May 1999)
Hypothetical biotechnology mega-mergersNature Biotechnology Strategic Planning (01 May 1999)
Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritisNature Medicine Article (01 Sep 2005)
